

CancerMPact® CancerLandscape™

A comprehensive overview of the oncology drug and trial landscape

Gain confidence with your clinical and commercial decision making in an evolving oncology landscape

Features

CancerLandscape provides a visual and interactive view of the drug and trial landscape with weekly updates. Use oncology-specific clinical and commercial filter options to make quick comparisons, uncover trends and identify threats/opportunities.

- Visual design provides intuitive user-experience
- Coverage of major registries - clinicaltrials.gov, EUCTR, jRCT
- Trial Change Analytics - capture key trial transitions and events
- Enhanced patient segmentation, line of therapy delineation and biomarker coverage
- “What’s New?” to track new trial/drug/companies
- Visualize trends and read the latest trial news
- Saved searches / custom views

Benefits

Drug/trial intelligence with oncology detail:

Query elements (e.g. line of therapy, biomarker) not easily standardized to better inform clinical and commercial decisions

Visual user interface:

Click to navigate and identify emerging targets, novel technologies, trial strategies, deal opportunities and link to benchmark and pivotal trials profiled within Treatment Architecture and Future Trends and Insights

Portable data:

Easily download graphics (pptx) and data (xlsx) for presentations and additional analyses

Clinical and scientific support:

Full access to the CancerMPact Oncology Support team



Search and refine

Trial

- Phase (I, I/II, II, II/III, III, IV, approved)
- Status (e.g. recruiting, completed)
- Arm (experimental, control)
- Country / region
- Domestic / global
- Start / end / primary completion date
- Registry (clinicaltrials.gov, EUCTR, jRCT)
- Primary endpoint (e.g. survival, response, safety)
- Pivotal trial outlook – links to Future Trends and Insights
- Benchmark trial reference – links to Treatment Architecture
- Event analytics to flag recent changes
- Published trials – links to PubMed
- Trial results - links to clinicaltrials.gov
- Latest news and events

Company

- Sponsor (trial)/owner (drug)
- Sponsor class (industry, academic)
- Size (private vs. public (small-, med-, large-cap))

Tumor

- Tumor type/subtype (mesh term)
- Patient segment (e.g. ECOG, fitness, platinum eligibility/sensitivity, Child-Pugh, risk status, transplant eligibility)
- Setting (1L, 2L, 3L, 4L+, maintenance, neo/adjuvant)
- Biomarker (full set of regulatory approved biomarkers, e.g. ALK, BRAF, FLT3, HRD, IDH, MSI, PDL1, RAS, TMB)

Drug

- Name (brand, generic, research)
- Target (e.g. PD-1, CD19, EGFR)
- Technology (e.g. ADC, mAb, CAR-T, bispecific, TKI)
- Immunotherapy combinations (mono, combo, ICI, non-ICI)
- Highest phase of development, by tumor type and overall

Example dashboard view



About Oracle Life Sciences

Oracle Life Sciences is a leader in cloud technology, pharmaceutical research, and consulting, trusted globally by professionals in both large and emerging companies engaged in clinical research and pharmacovigilance, throughout the therapeutic development lifecycle, including pre- and post-drug launch activities. With more than 20 years' experience, Oracle Life Sciences is committed to supporting clinical development and leveraging real-world evidence to deliver innovation and accelerate advancements – empowering the Life Sciences industry to improve patient outcomes. Learn more at oracle.com/lifesciences